Revolution Medicines Inc.
Revolution Medicines Reports Q4 2024 Financial Results and Clinical Progress
Summary
Revolution Medicines, Inc. reported its financial results for the quarter and full year ended December 31, 2024, revealing a net loss of $194.6 million for Q4 and $600.1 million for the full year. The company's cash position stood at $2.3 billion as of December 31, 2024, supported by a recent public equity offering that raised $823 million. The company also provided updates on its clinical trials, including the ongoing Phase 3 RASolute 302 trial for daraxonrasib in metastatic pancreatic cancer and the initiation of a Phase 3 trial for daraxonrasib in non-small cell lung cancer. The company anticipates completing enrollment in the RASolute 302 trial in 2025 and initiating two additional trials for pancreatic cancer in the second half of 2025.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement